Company

Gilead Sciences, Inc.

Headquarters: Foster City, CA, United States

Founded: June 22, 1987

Employees: 14,400

CEO: Mr. Daniel P. O'Day

NASDAQ: GILD -0.83%

Market Cap

$105.27 Billion

USD as of Jan. 1, 2024

history Market Cap History

Company Description

Gilead Sciences, Inc., is a pharmaceutical and biotechnology company focusing on antiviral drugs to treat HIV, hepatitis B, hepatitis C, and influenza, notably producing and commercializing the blockbuster drugs Harvoni and Sovald. Besides, Gilead conducts research to develop a pipeline of new drugs and treatments and it also considers the acquisition of other blockbuster drugs.

Gilead Sciences, Inc. market capitalization over time

Evolution of Gilead Sciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Gilead Sciences, Inc.

Detailed Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Product & Services

AmBisome Atripla Biktarvy Complera Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan Macugen Odefsey Ranexa Sovaldi Stribild Tamiflu Truvada Tybost Veklury Vemlidy Viread Vosevi Yescarta Zydelig

Key People

Daniel O' Day (CEO and Chairman) Andrew Dickinson (CFO) Tomáš Cihlář (Vice president, and Senior Director, Biology)

Financials

Revenue: US$22.45 billion (2019)

Operating income: US$4.29 billion (2019)

Net income: US$5.39 billion (2019)


Total assets: US$61.63 billion (2019)

Total equity: US$22.65 billion (2019)

Details

Headquarters:

333 Lakeside Drive

Foster City, CA 94404

United States

Phone: 650 574 3000

Fax: 650 578 9264